The implications of mitochondria in doxorubicin treatment of cancer in the context of traditional and modern medicine

• Main Authors: Leonardo da Cunha Menezes Souza (Author), Meng Chen (Author), Yuji Ikeno (Author), Daisy Maria Fávero Salvadori (Author), Yidong Bai (Author)
• Format: Book
• Published: World Scientific Publishing, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2575-9000; 2575-9019; 10.1142/S2575900020300076
• Keywords: doxorubicin; cancer treatment; mitochondria; traditional chinese medicine; Other systems of medicine; RZ201-999
• Source: Traditional Medicine and Modern Medicine, Vol 3, Iss 4, Pp 239-254 (2020)

Doxorubicin (DOX) is an antibiotic anthracycline extensively used in the treatment of different malignancies, such as breast cancer, lymphomas and leukemias. The cardiotoxicity induced by DOX is one of the most important pathophysiological events that limit its clinical application. Accumulating evidence highlights mitochondria as a central role in this process. Modulation of mitochondrial functions as therapeutic strategy for DOX-induced cardiotoxicity has thus attracted much attention. In particular, emerging studies investigated the potential of natural mitochondria-targeting compounds from Traditional Chinese Medicine (TCM) as adjunct or alternative treatment for DOX-induced toxicity. This review summarizes studies about the mechanisms of DOX-induced cardiotoxicity, evidencing the importance of mitochondria and presenting TCM treatment alternatives for DOX-induced cardiomyopathy.